Standard Biotools Inc (LAB) Stock Forecast & Price Target
Standard Biotools Inc · NASDAQ
$0.79+0.02 (+3.17%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Standard Biotools Inc, 0 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $1.35 to $1.35, so the covering firms are broadly aligned. The average target of $1.35 sits 70% above the current $0.79. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.02 next quarter toward $-0.01 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Hold
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Standard Biotools Inc.
As of Jul, 0 of 1 firms rate LAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LAB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.02
Range $-0.02 – $-0.02 · 1 analysts · -75% YoY
Next period, 1 analysts expect Standard Biotools Inc to earn $-0.02 a share (range $-0.02 – $-0.02), versus $-0.08 a year earlier. Full-year consensus is $0.03, growing to $-0.01 the year after.
REVENUE · NEXT QUARTER
$18.4M
Range $18.0M – $18.8M · 1 analysts · -6% YoY
Revenue is expected to reach $18.4M (range $18.0M – $18.8M), -5.9% year-over-year. Full-year consensus is $82.5M, rising to $84.1M next year.
Top analysts covering Standard Biotools Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LAB.
#1
Paul Knight
Keybanc · Rank #296
Hold
No targeton LAB
Overall win rate
32%
+ Follow
#2
Daniel Brennan
TD Cowen
Buy
$2.50+214.7% to target
Coverage
—
+ Follow
#3
KB
Kyle Boucher
TD Cowen
Hold
$1.35+69.9% to target
Coverage
—
+ Follow
LAB stock forecast FAQ
What is LAB's average 12-month price target?+
The 1 analysts with a live target average $1.35 for Standard Biotools Inc over the next 12 months, ranging from a $1.35 high to a $1.35 low.
Is LAB stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover LAB?+
1 analysts have an active rating on Standard Biotools Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering LAB?+
Among analysts who currently cover LAB, Paul Knight of Keybanc has the strongest overall Quantellect track record (Rank #296). Their current call is Hold.
What is Standard Biotools Inc's projected EPS for next quarter?+
The consensus estimate is $-0.02 per share (range $-0.02 – $-0.02) across 1 analysts. Full-year EPS is projected at $0.03, rising to $-0.01 the following year.
How much revenue is Standard Biotools Inc expected to report next quarter?+
Consensus revenue is $18.4M (range $18.0M – $18.8M). Full-year revenue is projected at $82.5M, growing to $84.1M next year.
Have analysts been upgrading or downgrading LAB lately?+
As of Jul, 0 of 1 firms rate LAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LAB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
